Author

Christian Agboton 1

1 Takeda,Zurich,Switze

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Stefan Schreiber, Silvio Danese, Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Bruce E. Sands, Dirk Lindner, Richard A. Lirio, Christian Agboton, Edward V. Loftus Jr.

OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE

Alessandro Armuzzi, Andreas Nikolaou, Michal Litkiewicz, Christian Agboton, Edouard Louis, Song Wang

REAL-WORLD EVIDENCE OF VEDOLIZUMAB ACHIEVING MUCOSAL HEALING AND ENDOSCOPIC IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS

Caroline Shaw, Rebecca Brown, Song Wang, Shashi Adsul, Christian Agboton, Pravin Kamble

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Niels Vande Casteele, William Sandborn, Brian G. Feagan, Severine Vermeire, Parambir Dulai, Julian Panés, Andres Yarur, Xavier Roblin, Shomron Ben-Horin, Iris Dotan, Mark Osterman, Dirk Lindner, Christian Agboton, Maria Rosario, Teresa Osborn

VEDOLIZUMAB ACHIEVES CORTICOSTEROID-FREE CLINICAL RESPONSE AND REMISSION IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD META-ANALYSIS

Caroline Shaw, Rebecca Brown, Song Wang, Shashi Adsul, Christian Agboton, Pravin Kamble

Item 1 - 5 / 5
1